Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of Volanesorsen in patients suffering from familial chylomicronemia syndrome (FCS), both before and during treatment periods

Trial Profile

A retrospective study of Volanesorsen in patients suffering from familial chylomicronemia syndrome (FCS), both before and during treatment periods

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Volanesorsen (Primary)
  • Indications Hyperlipoproteinaemia type I
  • Focus Adverse reactions
  • Acronyms ReFOCUS study
  • Most Recent Events

    • 13 Jun 2018 According to an Akcea Therapeutics media release, results from this trial were published in the journal Expert Review of Cardiovascular Therapy.
    • 03 May 2018 New trial record
    • 26 Apr 2018 According to a Akcea Therapeutics media release, results from this study will be presented at the National Lipid Association (NLA) Scientific Sessions on Apr 2018 and at the European Atherosclerosis Society (EAS) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top